{"id":"11375958-976d-5c1a-860f-35b7369d8ed6","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-in-vivo-and-behavioural","predicate":"reduces","statement":"In APPsw transgenic mice, ibuprofen effects were not mediated by alterations in amyloid precursor protein expression or oxidative damage, six months of treatment in transgene-positive females decreased open field behaviour to values similar to transgene-negative mice and reduced caspase activation per plaque, and a shorter three month trial begun at 14 months produced a significant treatment effect on amyloid-beta levels with reductions of both soluble amyloid-beta and amyloid-beta 42 most marked in entorhinal cortex, the magnitude of the effect on soluble amyloid-beta not depending on treatment duration.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"54548339-eb56-54c3-95c6-8e45bd95ccca","mechanism_event_label":"In mice bred to deposit amyloid, the drug lowered the peptide and changed their behaviour back toward normal.","subject":{"id":"b429f269-1d01-59f4-881a-868de0849d0d","slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"},"object":{"id":"40345ff7-8848-5083-ba88-e70ee16e7234","slug":"amyloid-beta-42","display_name":"Amyloid-beta 42, the 42-residue isoform","entity_type_key":"peptide"},"evidence_count":1,"mechanism_event":{"id":"54548339-eb56-54c3-95c6-8e45bd95ccca","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-in-vivo-and-behavioural-event","event_type":"biochemical_relationship","label":"In mice bred to deposit amyloid, the drug lowered the peptide and changed their behaviour back toward normal.","description":"In APPsw transgenic mice, ibuprofen effects were not mediated by alterations in amyloid precursor protein expression or oxidative damage, six months of treatment in transgene-positive females decreased open field behaviour to values similar to transgene-negative mice and reduced caspase activation per plaque, and a shorter three month trial begun at 14 months produced a significant treatment effect on amyloid-beta levels with reductions of both soluble amyloid-beta and amyloid-beta 42 most marked in entorhinal cortex, the magnitude of the effect on soluble amyloid-beta not depending on treatment duration.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"d7899911-b0e5-59b9-8647-210e45b821a0","slug":"appsw-mouse","display_name":"The APPsw / Tg2576 transgenic mouse","entity_type_key":"cellular_process"},"role":"model","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5fa4f8e5-53e0-54db-818b-d6b51103b417","slug":"entorhinal-cortex","display_name":"Entorhinal cortex","entity_type_key":"cell_type"},"role":"affected_region","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"320a83c1-81f2-5874-993a-d409bfb195fb","slug":"app-processing","display_name":"Amyloid precursor protein processing","entity_type_key":"cellular_process"},"role":"unchanged_process","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"b429f269-1d01-59f4-881a-868de0849d0d","slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"40345ff7-8848-5083-ba88-e70ee16e7234","slug":"amyloid-beta-42","display_name":"Amyloid-beta 42, the 42-residue isoform","entity_type_key":"peptide"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ibuprofen-research/11755007.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"85bd65aa6bff20262f11cfa0cd26a25a327aff114898605cea3a0cc05459192b\", \"start_char\": 0, \"end_char\": 1213, \"text_sha256\": \"85bd65aa6bff20262f11cfa0cd26a25a327aff114898605cea3a0cc05459192b\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Six month and three month ibuprofen treatment of APPsw Tg2576 transgenic mice with behavioural and biochemical endpoints","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Ibuprofen begun at different ages, with soluble and insoluble amyloid-beta and open field behaviour measured","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"An in vivo test with a behavioural endpoint and two treatment durations. A transgenic model of amyloid deposition, which is not Alzheimer’s disease.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.","comparator":null,"unit":null,"notes":"","entity":{"slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Mouse","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"In mice bred to deposit amyloid, the drug lowered the peptide and changed their behaviour back toward normal.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ibu-p11755007] Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. (2001). https://pubmed.ncbi.nlm.nih.gov/11755007/ DOI: 10.1016/s0197-4580(01)00299-8","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Brain","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"59b49842-251f-5536-bb29-14b807d72f76","evidence_kind":"source_excerpt","locator":"Lines 435-446","start_line":435,"end_line":446,"excerpt":"### ibu-in-vivo-and-behavioural\nIn APPsw transgenic mice, ibuprofen effects were not mediated by alterations in amyloid precursor protein expression or oxidative damage, six months of treatment in transgene-positive females decreased open field behaviour to values similar to transgene-negative mice and reduced caspase activation per plaque, and a shorter three month trial begun at 14 months produced a significant treatment effect on amyloid-beta levels with reductions of both soluble amyloid-beta and amyloid-beta 42 most marked in entorhinal cortex, the magnitude of the effect on soluble amyloid-beta not depending on treatment duration.\nCondition category: normal\nnutrient_topic: Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.\nplain_language: In mice bred to deposit amyloid, the drug lowered the peptide and changed their behaviour back toward normal.\norganism: Mouse\ntissue_or_cell_type: Brain\nexperimental_model: Six month and three month ibuprofen treatment of APPsw Tg2576 transgenic mice with behavioural and biochemical endpoints\nlimitations: An in vivo test with a behavioural endpoint and two treatment durations. A transgenic model of amyloid deposition, which is not Alzheimer’s disease.\nexposure: Ibuprofen begun at different ages, with soluble and insoluble amyloid-beta and open field behaviour measured\nevidence_span: {\"source_cache\": \"artifacts/ibuprofen-research/11755007.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"85bd65aa6bff20262f11cfa0cd26a25a327aff114898605cea3a0cc05459192b\", \"start_char\": 0, \"end_char\": 1213, \"text_sha256\": \"85bd65aa6bff20262f11cfa0cd26a25a327aff114898605cea3a0cc05459192b\"}\n[ibu-p11755007] Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. (2001). https://pubmed.ncbi.nlm.nih.gov/11755007/ DOI: 10.1016/s0197-4580(01)00299-8","model_system":"Six month and three month ibuprofen treatment of APPsw Tg2576 transgenic mice with behavioural and biochemical endpoints","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ibu-p11755007] Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. (2001). https://pubmed.ncbi.nlm.nih.gov/11755007/ DOI: 10.1016/s0197-4580(01)00299-8","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"31c4939d-f520-55c0-973b-224743caf245","stable_key":"import-3238e4f0-8d45-5c72-8624-6e9a8b20527c","title":"Ibuprofen: the enantiomer that works, the one that was called inactive, the one-way chemistry that turns one into the other, and the targets that are not cyclooxygenase (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"cc2b388178f97f5906b66ecbe441fc5c86d51fd645947c5260fb0b4bdb4bcd21","revision_id":"0b4e5c65-05d3-5430-a4cd-8d6a03647dcb","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}